106
Participants
Start Date
October 27, 2020
Primary Completion Date
July 6, 2021
Study Completion Date
July 15, 2021
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
Placebo
Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Topical corticosteroids (TCS)
TCS administered as needed.
LEO Investigational Site, Nagoya
LEO Investigational Site, Ichikawa
LEO Investigational Site, Ichikawa-shi
LEO Investigational Site, Chikushino-shi
LEO Investigational Site, Asahikawa
LEO Investigational Site, Chuo-Ku-Sapporo
LEO Investigational Site, Obihiro-shi
LEO Investigational Site, Sapporo
LEO Investigational Site, Sapporo
LEO Investigational Site, Nishinomiya
LEO Investigational Site, Nonoichi
LEO Investigational Site, Kagoshima
LEO Investigational Site, Kawasaki-shi
LEO Investigational Site, Yokohama
LEO Investigational Site, Yokohama
LEO Investigational Site, Kamigyō-ku
LEO Investigational Site, Tokyo
LEO Investigational Site, Osaka
LEO Investigational Site, Sakai-shi
LEO Investigational Site, Toyonaka-shi
LEO Investigational Site, Koto-ku
LEO Investigational Site, Setagaya City
LEO Investigational Site, Shinjuku-ku
LEO Investigational Site, Shinjuku-ku
LEO Investigational Site, Fukuoka
Lead Sponsor
LEO Pharma
INDUSTRY